DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Sotagliflozin
Sotagliflozin
Natural Products As Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors
Annexes to the Annual Report of the European Medicines Agency 2014
Identification of SGLT2 Inhibitor Ertugliflozin As a Treatment
Dapagliflozin As an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of This Combination
Sotagliflozin As an Adjunct to Insulin for Type 1 Diabetes
Growing Our Future in Diabetes Care: Where Are We Now and Where Are We Going?
Standards of Medical Care in Diabetes—2019
Clinical Trials Appendices R&D Pipeline – New Molecular Entities(*)
FDA Introductory Remarks January 17, 2019 Endocrinologic and Metabolic Drugs Advisory Committee Meeting
Appraisal of Sotagliflozin As Adjunctive Therapy for Type 1 Diabetes
SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?
The Effects of SGLT2 Inhibitors on Lipid Metabolism
New Medications on the Horizon Diana Isaacs Andrew Bzowyckyj
Adverse Effects and Safety of SGLT2 Inhibitor Use Among Patients with Type 2 Diabetes: Findings from RCT Evidence
Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus
Sodium-Dependent Glucose Cotransporters
Sitagliptin (Januvia®, Xelevia®)
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahr 2020
Top View
Northeast Iowa Medical Foundation Clinical Study of Type Two Diabetes
Lexicon Pharmaceuticals, Inc. Our Strategic Intent – Innovations That Transform Standard of Care
Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians
Sodium–Glucose Cotransporter 2 Inhibitors: a Case Study in Translational Research
FDA Briefing Document Endocrinologic and Metabolic
A Review of Recent Developments in the Pharmacological Prevention and Treatment of Endocrinopathic Laminitis
Australasian Anaesthesia 2019
SGLT2 Inhibitor Therapy Improves Blood Glucose but Does Not Prevent Diabetic Bone Disease in Diabetic DBA/2J Male Mice Kathryn M
Appendix – Literature Search & In-Excluded Studies
Non-Insulin Medications to Manage Type 1 Diabetes Jennifer N
Emergence of SGLT2 Inhibitors As Powerful Antioxidants in Human Diseases
Summary of the Risk Management Plan for Zynquista (Sotagliflozin)
The Management of Diabetes in Primary Care Kelly Krawtz, Pharmd, BCPS, BCACP
Guidelines for ATC Classification and DDD Assignment 2021
Role of Selective Sodium-Glucose Co-Transporter- 2 Inhibitors in Managing Cardio-Renal Complications in Type 2 Diabetes Mellitus
Effect of Sodium Glucose Cotransporter 2 Inhibitors with Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus
2 Inhibitors in Hospitalized Patients with Acute Heart Failure
Sotagliflozin Is As an Adjunct to Insulin Therapy to Improve
Sotagliflozin for Type 2 Diabetes Mellitus
LY-900014 (Ultra-Rapid Lispro) for Adults with Type 1 Diabetes Mellitus
Efficacy and Safety of Dual SGLT 1/2 Inhibitor Sotagliflozin in Type 1 Diabetes
Sotagliflozin, the First Dual SGLT Inhibitor
A Complete Review of Empagliflozin
Addendum. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
2018 Diabetes Pharmacotherapy Overview
Sodium–Glucose Transporter-2 Inhibitors for Prevention And
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents
Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight Or Obesity Harold E
Citizen Petition Date: June 24, 2020 Division of Dockets Management
Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease